Across the world, demand for mental-health support is exploding. Anxiety, depression, and sleep disorders are no longer ...
Lund, Sweden, December 15, 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced a reorganization of its European and International Commercial and Medical Affairs operations, ...
The board of directors of Simris Group AB (publ) (“Simris Group” or the “Company”) has today resolved on a directed issue of units consisting of one (1) class B share and two (2) warrants of series ...
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that its therapeutic research arm, Caris Discovery, ...
First CTA authorization marks nChroma’s transition to a clinical-stage company; first patient dosing in Phase 1/2 trial planned for early 2026 Preclinical studies demonstrated CRMA-1001 delivers ...
Lund, Sweden, 16 December 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that GOOD-IDES-02, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) ...
On 27 July 2025, the board of directors of Simris Group AB (publ) ("Simris Group" or the "Company") resolved, by virtue of the authorisation granted by the annual general meeting held on 28 May 2025, ...
PALO ALTO, CALIFORNIA / ACCESS Newswire / December 17, 2025 / Bioz, Inc., the leading AI-powered platform that transforms published scientific data into actionable product insights, is pleased to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback